Filing Flows › Gyre Therapeutics (GYRE) › Gross margin
Gyre Therapeutics (GYRE) gross margin by quarter
Gyre Therapeutics' gross margin was 94.7% in Q3 2025 (third quarter 2025), -1.0 pts from Q2 2025. Over the last 3 quarters it ranged from 94.7% (Q3 2025) to 95.9% (Q1 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2025 | 94.7% | -1.0 pts | — |
| Q2 2025 | 95.7% | -0.2 pts | — |
| Q1 2025 | 95.9% | — | — |
Q3 2025 at a glance
Gyre Therapeutics, Q3 2025: revenue $30.6M (+20% year over year), operating margin 22.7%, net earnings $5.9M, operating cash flow $4.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Gyre Therapeutics' gross margin?
Gyre Therapeutics' gross margin was 94.7% in Q3 2025 (third quarter 2025), -1.0 pts from Q2 2025.
How has Gyre Therapeutics' gross margin changed?
Over the last 3 quarters it ranged from 94.7% (Q3 2025) to 95.9% (Q1 2025).